Wayne Pisano Acquires 5,000 Shares of Altimmune (NASDAQ:ALT) Stock

Altimmune, Inc. (NASDAQ:ALT) Director Wayne Pisano acquired 5,000 shares of the stock in a transaction on Thursday, January 8th. The shares were bought at an average price of $4.08 per share, with a total value of $20,400.00. Following the purchase, the director directly owned 13,498 shares of the company’s stock, valued at $55,071.84. The trade was a 58.84% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Altimmune Stock Down 1.5%

Shares of NASDAQ ALT traded down $0.06 during trading on Friday, reaching $4.02. The company had a trading volume of 3,065,780 shares, compared to its average volume of 8,400,127. Altimmune, Inc. has a 12-month low of $2.90 and a 12-month high of $7.73. The company has a quick ratio of 17.18, a current ratio of 17.18 and a debt-to-equity ratio of 0.08. The business’s 50-day moving average is $4.49 and its 200 day moving average is $4.17. The stock has a market cap of $419.45 million, a PE ratio of -3.76 and a beta of 0.04.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.08. Altimmune had a negative return on equity of 54.79% and a negative net margin of 419,575.00%.The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. As a group, equities analysts forecast that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on ALT shares. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Altimmune in a report on Monday, October 20th. Citizens Jmp cut their target price on Altimmune from $15.00 to $14.00 and set a “market outperform” rating on the stock in a research note on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a report on Monday, December 29th. Finally, Citigroup restated a “market outperform” rating on shares of Altimmune in a research note on Wednesday, November 12th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $16.60.

Institutional Investors Weigh In On Altimmune

Large investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. bought a new position in shares of Altimmune during the 3rd quarter valued at $38,000. BNP Paribas Financial Markets increased its position in Altimmune by 108.5% during the second quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock valued at $39,000 after acquiring an additional 5,253 shares during the last quarter. Kingswood Wealth Advisors LLC bought a new position in Altimmune in the second quarter valued at about $40,000. Prudential Financial Inc. purchased a new position in Altimmune in the second quarter worth about $43,000. Finally, Sequoia Financial Advisors LLC purchased a new position in Altimmune in the third quarter worth about $46,000. Institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.